Sugi Predict

Sugi Predict / Compounds / SCHEMBL2676189

SCHEMBL2676189

SCHEMBL2676189

CCn1cc(-c2cc(Oc3ccc4nc(N[C@@H](CO)CC(C)C)sc4c3)ccn2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 4/20 0.43
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PI4KA P42356 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ PI4KB Q9UBF8 1/20 0.38
▸ PIM1 P11309 4/20 0.38
▸ NPC1 O15118 6/20 0.35
▸ RAB9A P51151 6/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ FGFR1 P11362 2/20 0.35
▸ FGFR2 P21802 2/20 0.35
▸ FGFR4 P22455 2/20 0.35
▸ FGFR3 P22607 2/20 0.35
▸ KDR P35968 2/20 0.35
▸ TP53 P04637 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676190 1.00 CSF1R (0.43) CSF1RPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL2678977 0.94 PIK3CD (0.40) CSF1RPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL2678973 0.94 PIK3CD (0.40) CSF1RPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL2677108 0.92 CSF1R (0.35) CSF1RNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2677829 0.92 CSF1R (0.35) CSF1RFGFR1FGFR2FGFR4FGFR3
SCHEMBL2677831 0.92 CSF1R (0.35) CSF1RFGFR1FGFR2FGFR4FGFR3
SCHEMBL2677110 0.92 CSF1R (0.35) CSF1RNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2676357 0.91 SYK (0.38) CSF1RPIK3CANPC1RAB9ASMN1; SMN2
SCHEMBL2676361 0.91 SYK (0.38) CSF1RPIK3CANPC1RAB9ASMN1; SMN2
SCHEMBL2677446 0.90 CSF1R (0.35) CSF1RPIK3CDPIK3CAPIK3CBPI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553854-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-06-30 — — US claimed
US-8710048-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2014-04-29 — — US disclosed
US-8710048-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2014-04-29 — — US disclosed
US-8710048-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2014-04-29 — — US disclosed
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-8173689-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2012-05-08 — — US disclosed
US-8173689-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2012-05-08 — — US disclosed
US-8173689-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2012-05-08 — — US disclosed
US-20100280006-A1 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2010-11-04 — — US disclosed
US-7553854-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-06-30 — — US disclosed
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG 2008-02-21 — — US disclosed
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG 2008-02-21 — — US disclosed
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG 2008-02-21 — — US disclosed
WO-2007121484-A2 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG (CH) 2007-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling CSF1R, CSF3R, FLT3 CSF1R 1/4885PIK3CD 3897/4885PIK3CA 2515/4885
US-20100280006-A1 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling CSF1R, CSF3R, FLT3 CSF1R 1/4885PIK3CD 3897/4885PIK3CA 2515/4885
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING CSF1R, CSF3R, FLT3 CSF1R 1/4885PIK3CD 3897/4885PIK3CA 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback